Relationship between glycated haemoglobin (HbA1c) point-of-care and laboratory testing in intensive care unit (ICU) patients with diabetes

Relationship between glycated haemoglobin (HbA1c) point-of-care and laboratory testing in ICU patients with diabetes

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12617000555358

Enrollment

Registered

2017-04-20

Start date

2017-06-16

Completion date

2017-07-31

Last updated

2019-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Point-of-care HbA1c testing in the intensive care setting may be advantageous for patients with diabetes who are admitted to ICU because including rapid availability of the result may guide insulin therapy. This may be of particular benefit for patients with poor glycemic control that are at a greater risk of hypoglycemic complications. However the accuracy of the HbA1c point of care testing has not been validated in the critically ill.

Interventions

This is a study evaluating the agreement between point-of-care HbA1c analysis when compared to laboratory analysis. ICU patients with known diabetes will have a capillary and arterial blood sample tested on a point -of-care HbA1c analyzer (Siemens DCA Vantage Analyzer). The same arterial sample will be sent to a central labratory for HbA1c analysis. In the case where an arterial sample is not available, a venous sample will be used.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Participants will include all patients with known diabetes admitted to the Intensive Care Unit (ICU).

Exclusion criteria

No exclusion criteria aside from opposite of inclusion criteria.

Outcome results